AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity | Nature Communications
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity | Nature Communications
Frontiers | Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth | Genetics
Cancers | Free Full-Text | Increased Non-Homologous End Joining Makes DNA-PK a Promising Target for Therapeutic Intervention in Uveal Melanoma | HTML
DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage | Nature Communications
PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer | eLife
Cancers | Free Full-Text | Increased Non-Homologous End Joining Makes DNA-PK a Promising Target for Therapeutic Intervention in Uveal Melanoma | HTML
Discovery and Development of Novel DNA-PK Inhibitors by Targeting the unique Ku-DNA Interaction | bioRxiv
Targeting ATM pathway for therapeutic intervention in cancer
DNA-PK Inhibition | DNA-PK Inhibitor Review
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity | Nature Communications
Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair
Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer | Scientific Reports
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions - ScienceDirect
DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage | Nature Communications
PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer | eLife
NU7441 (KU-57788) | ≥99%(HPLC) | Selleck | DNA-PK inhibitor
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity | Nature Communications
DNA-PK is activated by DSB-inducing agents and is inhibited by NU7441.... | Download Scientific Diagram
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours | British Journal of Cancer
Structural insights into inhibitor regulation of the DNA repair protein DNA- PKcs | Nature
Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair
DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer - ScienceDirect
Discovery and Development of Novel DNA-PK Inhibitors by Targeting the unique Ku-DNA Interaction | bioRxiv
